FOLH1 and posterior cortical atrophy: In the ORIOLE phase II trial [16], SABR improved outcomes with significant advantages in terms of median progression-free survival (PFS) (unreached at 24 months follow-up vs. 11.8 months; HR 0.26; 95% CI: 0.09–0.76; p = 0.006) and distant metastasis-free survival (29.0 vs. 6.0 months; HR 0.19; 95% CI: 0.07–0.54; p < 0.001) in men who received consolidation of all of the disease localizations detected by PSMA-PET (baseline data blinded by protocol), supporting the use of molecular imaging in conjunction with metastasis-directed therapy (MDT) for patients with oligometastatic PCa.